Date: May 29th, 2019

NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01

Shanghai, China, May 29th, 2019. NanoMab announced a collaboration with Lantheus Medical Imaging, Inc. (LMI) to provide 99mTc-NM-01 as clinical research tool, together with support and analytics, to pharmaceutical companies and the largest academic centers conducting clinical research in immuno-oncology in North America and Europe.

99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment

Also see link: Lantheus Announces Strategic Collaboration with NanoMab to Provide a Novel Biomarker for Clinical Development and Management of Immuno-Oncology Therapies